SCHEMBL16626639

SCHEMBL16626639

Cc1ccc(Cc2ccc3c(CN(C)C(=O)OC(C)(C)C)cn(S(=O)(=O)c4cccnc4)c3c2)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
ALK Q9UM73 1/20 0.34
TNFSF11 O14788 2/20 0.34
IDE P14735 2/20 0.34
HTR6 P50406 5/20 0.33
PTGER2 P43116 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HTR2C P28335 1/20 0.32
SLC6A4 P31645 1/20 0.32
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
CYP19A1 P11511 1/20 0.31
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619292 0.90 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DALK
SCHEMBL16626752 0.88 HTR6 (0.37) PDE4APDE4BPDE4CPDE4DALK
SCHEMBL16626633 0.86 HTR6 (0.38) PDE4APDE4BPDE4CPDE4DIDE
SCHEMBL16626635 0.86 HTR6 (0.38) PDE4APDE4BPDE4CPDE4DIDE
SCHEMBL16626414 0.84 HTR6 (0.39) PDE4APDE4BPDE4CPDE4DIDE
SCHEMBL16626645 0.83 HTR6 (0.41) PDE4APDE4BPDE4CPDE4DTNFSF11
SCHEMBL19971435 0.81 HTR6 (0.40) PDE4APDE4BPDE4CPDE4DTNFSF11
SCHEMBL16626636 0.81 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DALK
SCHEMBL19971352 0.81 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DALK
SCHEMBL19971398 0.81 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI PDE4A 2460/4885PDE4B 1996/4885PDE4C 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.